Advances in the Treatment of Metastatic Prostate Cancer

Jong Chul Park; Mario A Eisenberger

doi:10.1016/j.mayocp.2015.10.010

Advances in the Treatment of Metastatic Prostate Cancer

Mayo Clin Proc. 2015 Dec;90(12):1719-33. doi: 10.1016/j.mayocp.2015.10.010.

Authors

Jong Chul Park¹, Mario A Eisenberger²

Affiliations

¹ Genito-Urinary Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, MD.
² Genito-Urinary Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, MD. Electronic address: eisenma@jhmi.edu.

PMID: 26653301
DOI: 10.1016/j.mayocp.2015.10.010

Abstract

During the past several years, there has been substantial progress in the development of treatments for advanced prostate cancer with the approval of multiple new life-prolonging agents using different mechanisms of action. Such progress was attainable because of advances in our understanding of the biology behind mechanisms of androgen receptor pathway activation, complex tumor-microenvironment interaction of bone metastasis, antitumor immunology, and new oncogenic pathways. Continuous efforts are being made to develop new therapeutics with novel mechanisms of action, define the optimal sequences and/or combinations of current agents, and identify reliable surrogate end points to facilitate new drug development.

Publication types

Review

MeSH terms

Humans
Male
Neoplasm Metastasis / pathology*
Neoplasm Metastasis / therapy*
Prostatic Neoplasms / pathology*
Prostatic Neoplasms / therapy*